🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — June 22, 2026

The June 22, 2026, filings reveal a market sharply bifurcated between aggressive strategic M&A and internal corporate governance adjustments. The most dominant theme is a wave of high-value, transformative acquisitions in the life sciences and industrial sectors, highlighted by AbbVie's $10.9 billion acquisition of Apogee Therapeutics and CRH's $8.5 billion acquisition of Arcosa. These deals signal strong conviction in targeted growth areas like immunology and infrastructure, with clear synergy targets and expected accretion. Concurrently, a significant number of filings detail leadership transitions, board appointments, and executive compensation changes, indicating a period of corporate restructuring and succession planning. However, this activity is tempered by notable risk flags, including shareholder dissent on equity plan dilutions at several firms, a failed director election at Pluri Inc., and the precarious financial positions of smaller biotechs like CervoMed, which highlight a challenging capital environment for early-stage companies. The overall picture is one of strategic repositioning by larger, well-capitalized players, while smaller entities face a more difficult path to growth and funding.

50 high priority 50 total filings
· daily

Insider Trading Pulse — June 22, 2026

The June 22, 2026 insider trading digest reveals a market characterized by starkly divergent management sentiment. A powerful cluster of bullish insider buying is concentrated in small-cap and micro-cap companies, particularly within the Chinese ADR space (Gaotu Techedu, Baozun) and select US industrials (Mission Produce, Energy Services of America), signaling deep-seated management conviction at depressed valuations. Conversely, significant bearish signals emanate from the biotech and semiconductor sectors, with high-materiality insider sales at uniQure (CEO sold $2.47M) and Kulicke & Soffa (Interim CEO sold $7.3M, nearly his entire stake), suggesting sector-specific headwinds. The data is also heavily populated with routine, neutral equity awards (Yum China, Omeros, Chegg), which are non-actionable for trading but indicate standard compensation practices. The most actionable themes are the divergence between insider buying in deeply undervalued Chinese ADRs and the selling in high-growth but cash-burning biotechs, alongside a notable capital return signal from Rex American Resources via a large insider sale. Overall, the data points to selective bottom-fishing opportunities in beaten-down sectors while flagging potential risks in biotech and semiconductor capital equipment.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — June 22, 2026

Over the reporting period, two Dow Jones Industrial Average constituents — JPMorgan Chase and Walmart — disclosed insider stock sales by senior executives, both executed under Rule 10b5-1 trading plans, which provides a layer of pre-planned structure and reduces the implication of opportunistic insider concern. The aggregate sale value was approximately $2.15 million, spread across two transactions: JPMorgan's General Counsel sold $1.81 million worth of shares, while Walmart's Executive Vice President sold $343,000. These insider sales occur in a context of no disclosed forward-looking guidance changes, capital allocation shifts, or material period-over-period trends from the filings. The absence of bullish insider buying, guidance raises, or operational catalysts against a backdrop of senior-level selling signals cautious positioning within two of the index's most stable, large-cap names. Portfolio-level analysis highlights a 'mixed-to-negative' insider sentiment pattern, with no offsetting positive signals such as share buyback announcements or dividend increases. The market implication is moderately bearish for sentiment, as insider selling in blue-chip stocks — even when pre-planned — often precedes periods of weaker relative performance, especially in the absence of countervailing fundamental catalysts.

2 high priority 2 total filings
· daily

US SEC Filings Daily Market Digest — June 22, 2026

Today's digest, spanning 50 filings from June 22, 2026, reveals a market landscape sharply divided between aggressive M&A and capital deployment activities and significant operational and financial distress among smaller issuers. Key macro themes include a pronounced uptick in M&A execution risk, particularly within the SPAC and de-SPAC ecosystem (Graf Global, RYVYL, Teamshares), and a surge in capital raises from cash-strapped biotech and micro-cap firms (CervoMed, MOBIX LABS), juxtaposed against strong shareholder returns from established players like News Corp and First United. The period-over-period data provides a stark contrast: Atlantic International Corp. saw revenues more than double (+143% YoY) via acquisition, but its net loss tripled to $30.7M, highlighting integration risk, while Pemex's operating income collapsed 38% YoY on falling export revenues. Geopolitical risk is a live wire, with Ryanair explicitly linking a recent share price drop to the war in Iran, while energy transition projects like Petrobras's new $1.2B biorefinery continue to advance. Insider activity was notable at Chart Industries and Baker Hughes, where management is navigating a complex EU antitrust review for a transformative merger. The overall sentiment is one of cautious opportunism, with clear pockets of value in companies with strong capital allocation and secular growth catalysts, but elevated risk in highly leveraged, cash-burning entities.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — June 22, 2026

The sole filing for the S&P 500 Consumer Discretionary stream is from Lowe's Companies Inc., reporting an insider sale by the EVP of Supply Chain. The transaction, while not large in absolute terms, is notable given the insider's role and the timing. No other filings or enriched data points are available for synthesis, limiting cross-company comparisons. The overall sentiment is negative, but the materiality is low, suggesting limited immediate market impact. Investors should monitor for additional insider activity or broader sector trends.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — June 22, 2026

The three S&P 500 Healthcare filings for June 22, 2026, reveal a sector bifurcated between long-term strategic bets and steady governance moves. AbbVie's $8.5B acquisition of Apogee Therapeutics is the standout event, a high-conviction pipeline bet on zumilokibart (APG777) that is expected to be accretive only from 2032, signaling a multi-year horizon and near-term EPS dilution. Centene's board appointment of Lauren Tyler, a seasoned financial services executive, points to a focus on governance and operational rigor amid ongoing strategic evolution. Zoetis's phantom stock award to a director is a routine retention mechanism with no market signal. The overarching theme is capital deployment for future growth (AbbVie) versus internal strengthening (Centene), with no immediate earnings catalysts from the filings. Period-over-period data was not available in the enriched filings, limiting trend analysis, but the forward-looking data from AbbVie creates a clear catalyst timeline for 2027-2032.

2 high priority 1 medium 3 total filings
· daily

US Earnings Financial Results SEC Filings — June 22, 2026

This digest of 34 filings reveals a bifurcated market: a handful of companies are executing transformative, albeit risky, growth strategies (e.g., Atlantic International, HawkEye 360), while a larger cohort of micro-cap entities (e.g., Stemtech, Global Interactive, Hong Yuan) are exhibiting severe financial distress, characterized by collapsing revenues, widening losses, and liquidity crises. A notable cluster of 12 Honda Auto Receivables Trusts filed routine compliance reports, offering no actionable financial insights. Key period-over-period trends include aggressive revenue growth from acquisitions (Atlantic International +143%, HawkEye 360 +116%) being offset by disproportionate expense growth and widening net losses, while established operators like Casey's General Stores (+10.2% revenue, +30.7% net income) show healthy, organic expansion. Insider trading activity was sparse, but the absence of insider buying in distressed micro-caps is a notable negative signal. The most critical development is the high number of going-concern risks and severe working capital deficits, suggesting a wave of micro-cap failures is possible. The primary market implication is a 'flight to quality' towards companies with positive cash flow and sustainable growth, as the speculative, acquisition-fueled growth model shows significant fragility.

34 high priority 34 total filings
· daily

US Executive Compensation Proxy SEC Filings — June 22, 2026

This batch of 11 proxy filings reveals a striking divergence in corporate trajectories, from a high-confidence pay-for-performance model at Albertsons (97% say-on-pay approval, 90% at-risk CEO pay) to a complete wind-down at Vicarious Surgical. A dominant theme is the prevalence of reverse stock split proposals—appearing in three filings (Jupiter Neurosciences, Linkhome Holdings, Professional Diversity Network)—signaling acute distress and Nasdaq compliance struggles among small-cap issuers. Period-over-period data at Park Aerospace shows a dramatic 520% surge in CEO 'compensation actually paid' to $1.03M, directly tied to improved operational metrics, offering a rare clean link between pay and performance. Insider activity is notably absent across the set, which is a neutral signal but reduces conviction signals. The most material risks cluster around governance failures (Vicarious Surgical's dissolution) and regulatory non-compliance (Professional Diversity Network's Nasdaq notice), while opportunities are limited to a few specific governance improvements and potential post-split turnarounds.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 22, 2026

The June 22, 2026, SEC filings reveal a concentrated wave of IPO registrations across infrastructure, tech, and medtech, with 8 new S-1s and 1 follow-on. Revenue growth is a common theme—MOBIX LABS (+50% YoY) and Ambiq Micro (+25% YoY) lead—but widening losses and cash burn raise sustainability concerns. Period-over-period data shows a clear pattern: revenue expansion at the expense of profitability, with Creatd posting a 30% revenue decline and a 335% net loss surge. Governance risks are prominent: dual-class structures at Gloo Holdings and VenHub Global concentrate voting power, while Catheter Precision's related-party warrants remain unexercisable pending stockholder approval. Financial distress flags include VenHub's $98.78M accumulated deficit and going concern doubt, and Aethlon's manufacturing delays and trial cancellations. Despite mixed sentiment, the pipeline offers high

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — June 22, 2026

The 50 filings for June 22, 2026, reveal a market dominated by corporate actions (M&A, buybacks, delistings) and financial distress signals, with a notable concentration of insolvency proceedings and promoter stake sales. Key period-over-period trends show a sharp divergence: Kalpataru Projects International reported robust 22% revenue and 82% profit growth, while Ishan Dyes and Chemicals swung to a deep loss on a 28% revenue decline. Insider activity is mixed, with a significant promoter sale at Adishakti Loha and Ispat (3.26% stake reduction) contrasting with a near-doubling of a promoter's stake at Jaro Institute of Technology. Capital allocation is active, highlighted by Bajaj Auto's massive ₹5,632.8 crore buyback and Hindustan Zinc's full release of a 50.1% share encumbrance. The most critical developments include the voluntary delisting of Tulive Developers, deferred revival plans at Amalgamated Electricity Co., and ongoing CIRP meetings for Videocon and Value Industries. Key themes include a wave of promoter restructuring via inter-se transfers, a focus on shareholder returns through buybacks and dividends, and persistent stress in the textile and chemicals sectors.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — June 22, 2026

This digest covers 50 regulatory filings on US executive and director changes from June 22, 2026. A dominant theme is significant leadership transitions at the CEO and CFO level across diverse sectors, including Domino's Pizza, NVE Corp, Johnson Outdoors, TaskUs, and PagerDuty. Several large-cap companies, such as A. O. Smith and Best Buy, are executing multi-year succession plans that underscore a focus on internal talent development. A high-conviction insider acquisition at IMA Tech saw a change of control, while notable shareholder dissent at MARA Holdings (40.8% withheld vote) and Oric Pharmaceuticals signals governance concerns. Mixed earnings guidance from Primoris Services Corp (adjusted EBITDA cut ~37%) is a major risk flag, while the overall tone of board appointments remains neutral to positive, with a notable addition of financial and operational expertise from companies like Centene and TD SYNNEX.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 22, 2026

Today's filings reveal a significant uptick in distress signals across micro-cap companies, with going concern risks, repeated defaults, and emergency equity offerings dominating the landscape. We see four companies in active liquidity crises (Algorhythm Holdings, Sable Offshore, Exyn Technologies) or warning of going concern uncertainty (CervoMed), while several others are forced to issue highly dilutive convertible notes or sell stock at deep discounts. A sharp bifurcation is evident: large-cap M&A (CRH/Arcosa, AbbVie/Apogee, Booz Allen) provides a bright spot, but for smaller firms, cash preservation through debt renegotiation, asset subleasing, and insider-funded advances is the prevailing theme. The average sentiment across all filings is neutral-to-mixed, with no sector-wide positive trends emerging in period-over-period comparisons as most filings lacked quantitative revenue or margin data. Key actionable insights include betting on the acquirers (CRH, AbbVie) and avoiding the most distressed micro-caps.

41 high priority 41 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 22, 2026

Today's digest of 50 USA board room changes reveals a significant uptick in CEO and C-suite successions, with a clear focus on internal promotions alongside a few notable departures linked to operational performance. The period-over-period data highlights divergent strategic outcomes: while companies like Domino's Pizza and PagerDuty leverage strong operational momentum for leadership transitions, Primoris Services exemplifies a direct link between board-level changes and severe financial underperformance, slashing its 2026 guidance by nearly 70%. A key theme is the increasing use of shareholder meetings as a barometer of investor sentiment, with director elections at ORIC Pharmaceuticals, MARA Holdings, and BridgeBio Oncology Therapeutics revealing notable opposition (19-41% withheld votes), signaling governance concerns or strategic disagreements. Insider activity is muted in the filings, but capital allocation moves, such as Primoris's $50M buyback and Domino's significant retail sales growth, provide context for new management's mandate. The synthesis underscores that while many changes are routine successions, several carry high materiality due to their linkage to strategic pivots, severe guidance revisions, or shareholder revolts.

50 high priority 50 total filings
· daily

USA Insider Trading Pulse — June 22, 2026

The June 22, 2026 insider trading pulse reveals a bifurcated market: heavy insider liquidation at firms like uniQure (CEO sold $2.47M under a 10b5-1 plan) and Belite Bio (CMO sold $707K), contrasting with strong insider conviction at beaten-down Chinese ADRs (Gaotu Techedu CEO bought $418K, Baozun executives bought ~$80K combined) and select value plays (Mission Produce director bought $3.23M). Director stock option grants at Omeros and restricted stock unit awards across Yum China's management team signal long-term alignment but no immediate market-moving conviction. Period-over-period comparisons from enriched data show no revenue/margin trends as filings are all Form 4s, but the pattern of Chinese management buying into weakness warrants attention as a potential contrarian signal. The most actionable themes are the Chinese education/e-commerce insider buying cluster, the high-conviction director purchase at Mission Produce, and the risk flags from the uniQure CEO sell-down and VinFast's massive preference share disposal.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 22, 2026

The USA M&A landscape on June 22, 2026, is dominated by SPAC activity and strategic divestitures. Two SPACs (Live Oak Acquisition Corp. V and Real Asset Acquisition Corp.) are progressing toward business combinations, with Live Oak facing a massive 80% shareholder redemption, signaling market skepticism. Kosmos Energy completed a divestiture of Equatorial Guinea assets, improving its balance sheet but reducing revenue. P10 (Ridgepost Capital) closed an acquisition of Stellus Capital Management, expanding its private credit platform. YHN Acquisition I extended its deadline, highlighting SPAC time pressure. Quantum Leap Acquisition Corp. and Safe & Green Holdings Corp. are in earlier stages. Key trends include high SPAC redemptions, strategic divestitures for debt reduction, and consolidation in asset management. No insider trading or forward guidance was reported in these filings.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 22, 2026

The overnight filing cycle reveals a market focused on corporate governance resets, M&A regulatory progress, and energy transition investments. Mixed earnings seasonality is evident with widening losses at Atlantic International and Pemex contrasting with a dramatic GAAP net income swing at America Great Health. A significant cluster of SPAC and de-SPAC activity (Graf Global/BIG3, RYVYL/RTB Digital) points to aggressive consolidation in thematic sectors. Notable insider and board moves include Ryanair's long-term CEO extension with ambitious performance hurdles and a leadership change at Panamera Holdings to drive a key combination. Regulatory milestones for major deals (Baker Hughes/Chart Industries, Paramount Skydance/WBD) are advancing, while litigation and audit risks at Bioceres and Webstar Technology present specific pitfalls. Capital allocation is mixed, with News Corp maintaining a $1B buyback and First United declaring a dividend, while CervoMed's dilutive $10M offering highlights the ongoing cash needs for pre-revenue biotechs.

21 high priority 29 medium 50 total filings
· daily

Defense Manufacturing Contracts — June 21, 2026

The single contract analyzed, a $1.26B award from the Department of Homeland Security (DHS) to Bollinger Shipyards Lockport, L.L.C., dominates the period and represents a significant civilian-agency defense procurement. This is a high-conviction, high-materiality signal for Bollinger, though the lack of pricing details and competition data introduces execution risk. The award underscores DHS's reliance on specialized shipyards for maritime security assets, a theme that benefits niche defense industrial base players. Key watch items include the contract's pricing structure (fixed-price vs. cost-plus) and whether this is a sole-source or competed award, which would materially alter the competitive moat assessment.

1 total filings
· daily

DHS Homeland Security Contracts — June 21, 2026

This single-day digest captures a single, highly material $1.26B Department of Homeland Security (DHS) contract awarded to Bollinger Shipyards Lockport, L.L.C. on December 19, 2025. Despite being classified under DHS, the contract is explicitly labeled as a defense contract, suggesting it supports a DHS mission with national security or military-adjacent applications, such as U.S. Coast Guard vessel construction. The award is 100% civilian-agency (DHS) with zero defense-related contracts in the period, but the $1.26B value and 7/10 signal strength make it the highest-conviction signal. Key risks include the lack of disclosed pricing structure (fixed-price vs. cost-plus) and competition details, which limit full risk assessment. Bollinger Shipyards is the sole beneficiary, creating a significant concentration risk for investors tracking DHS or defense shipbuilding exposure.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 21, 2026

This digest covers a single, massive $1.78B contract awarded to Leidos Biomedical Research Inc. by the Department of Health and Human Services (HHS), representing a purely civilian healthcare sector award with no defense exposure. The contract is a high-conviction bullish signal for Leidos, given its size relative to typical biomedical research awards, though the lack of pricing and competition details introduces execution and budget risk. The dominant theme is HHS's continued reliance on Leidos for large-scale biomedical research support, likely tied to the National Institutes of Health (NIH) mission. Key watch items include the contract's fixed-price vs. cost-plus structure and potential vulnerability to HHS budget reallocations or continuing resolution (CR) impacts in future fiscal years.

1 total filings
· daily

New Federal Contractors — June 21, 2026

Over a single day, June 21, 2026, two massive civilian-agency contracts totaling $3.04B were awarded, with zero defense-related obligations. The dominant theme is dual-use infrastructure: a $1.78B HHS contract to Leidos Biomedical Research for health/biodefense work, and a $1.26B DHS contract to Bollinger Shipyards for homeland security vessel construction. The highest-conviction signal is the sheer size and sole-source-like nature of both awards, suggesting deep incumbency or urgent mission need. A key risk is the lack of competition data—both awards may be sole-source or limited-competition, raising protest vulnerability and pricing opacity for investors.

2 total filings